Hepatocyte Growth Factor Regulates E Box–Dependent Plasminogen Activator Inhibitor Type 1 Gene Expression in HepG2 Liver Cells
- 1 October 2006
- journal article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 26 (10) , 2407-2413
- https://doi.org/10.1161/01.atv.0000240318.61359.e3
Abstract
Objective— We sought to determine the etiologic mechanism of pleiotropic growth factor, hepatocyte growth factor (HGF), as a regulator of hepatic synthesis of plasminogen activator inhibitor (PAI)-1, the physiological inhibitor of fibrinolysis and a potential inducer of atherothrombosis. Methods and Results— HGF increased PAI-1 mRNA expression and PAI-1 protein accumulation in the conditioned media of human liver-derived HepG2 cells, and increased hepatic PAI-1 mRNA expression in vivo in mice. HGF-inducible PAI-1 mRNA was attenuated by U0126, a specific inhibitor of mitogen-activated protein kinase (MAPK) kinase, and genistein, an inhibitor of tyrosine kinase. HGF increased the human PAI-1 promoter (−829 to +36 bp) activity, and deletion and mutation analysis uncovered a functional E box (5′-CACATG-3′) at positions −158 to −153 bp. Electrophoretic mobility shift assays demonstrated that this E box binds upstream stimulatory factors (USFs). HGF phosphorylated USFs through MAPK and tyrosine kinase pathways. Co-transfection of USF1 expression vector increased PAI-1 promoter activity. Sterol regulatory element-binding protein-1 attenuated HGF-inducible PAI-1 promoter activity. Conclusions— Because USFs are involved in the regulation of carbohydrates and lipid metabolism, HGF-mediated PAI-1 production may provide a novel link between atherothrombosis and metabolic derangements. Targeting HGF signaling pathway may modulate the thrombotic risk in high-risk patients.Keywords
This publication has 23 references indexed in Scilit:
- Metabolic SyndromeCirculation, 2005
- Hypofibrinolysis in the insulin resistance syndrome: implication in cardiovascular diseasesJournal of Internal Medicine, 2004
- Obesity is associated with increased levels of circulating hepatocyte growth factorJournal of the American College of Cardiology, 2003
- Prognostic Significance of Angiogenic Growth Factor Serum Levels in Patients With Acute Coronary SyndromesCirculation, 2003
- Hepatocyte growth factor: from diagnosis to clinical applicationsClinica Chimica Acta; International Journal of Clinical Chemistry, 2002
- Hepatocyte growth factor as a potential predictor of the presence of atherosclerotic aorto-iliac artery diseaseAmerican Heart Journal, 2002
- Relationships between Fibrinolytic and Inflammatory Parameters in Human Adipose Tissue: Strong Contribution of TNFα Receptors to PAI-1 LevelsThrombosis and Haemostasis, 2002
- Plasminogen-Activator Inhibitor Type 1 and Coronary Artery DiseaseNew England Journal of Medicine, 2000
- Role of Hepatocyte Growth Factor in Breast Cancer: A Novel Mitogenic Factor Secreted by AdipocytesDNA and Cell Biology, 1994
- Hepatocyte growth factor stimulates expression of plasminogen activator inhibitor type 1 and tissue factor in HepG2 cellsBlood, 1994